Aller au contenu
NOSA – Breathe with care

Relations investisseurs

Medtech suédoise pour le nez – au travail, au quotidien et pour votre odorat.

Dernier communiqué

NOSA announces that MDR certificates have been issued for Nozoil

Nosa Plugs AB (publ) (“NOSA” or the “Company”) announces that MDR certificates have been issued for Nozoil® Nasal Spray Original and Nozoil® Nasal Spray Menthol. The products are Class IIa medical devices. The certificates were issued on 5

L'action

Nosa Plugs AB (publ)

Symbole
NOSA
ISIN
SE0006994539
Place de cotation
Nasdaq First North Growth Market Stockholm

Dernier rapport

Nosa Plugs AB Interim Report for the Third Quarter 2026

6 novembre 2026

Télécharger le PDFRapports

Prochain événement

Calendrier financier: upcoming dates are published in the interim reports.

Calendrier financier

Interviews vidéo

Toutes les présentations

Financial targets

Short-term financial targets – 2025–2026

Growth target
Net sales of at least SEK 50 million in 2026.
Profitability target
Positive EBITDA from Q4 2025 and an EBITDA margin of at least 15 per cent in 2026.

Medium-term financial targets – 2027–2028

Growth target
Average organic net sales growth of at least 25 per cent per year.
Profitability target
EBITDA margin of at least 18 per cent.
Capital structure
Net debt in relation to EBITDA shall not exceed 3 times.
Dividend policy
Surplus shall be distributed to shareholders when free cash flow exceeds available investments in profitable growth. Dividends require that the capital structure target is met.

Going forward, NOSA will also continue to evaluate acquisition opportunities within ear, nose and throat (ENT).

Communiqués

Tous les communiqués
Réglementaire Rapport

Nosa Plugs AB Interim Report for the Third Quarter 2026

This English version is a translation of the Swedish quarterly report of Nosa Plugs AB (publ). In the event of any discrepancies, the Swedish version shall prevail. Financial performance 1 July - 30 September 2026 Net sales 10,232 TSEK (3,6

NOSA signs agreement with SEDA S.p.A. and strengthens its presence in the Italian healthcare market

Nosa Plugs AB (publ) has today, through its subsidiary NoseOption AB (“NOSA” or the “Company”), entered into a distribution agreement with Italian company SEDA S.p.A. (“SEDA”) for the sale of NOSA Odor control, NOSA Microbial control and NO

NOSA signs agreement with Galls and launches NOSA Odor Control in the U.S.

Nosa Plugs AB (publ) (“NOSA” or the “Company”) has entered into a distribution agreement with U.S.-based Galls, LLC, for the sale of NOSA Odor Control in the United States. The agreement has been entered into through NOSA’s U.S. subsidiary,

Equity research

Analyses, commentaires et interviews sur Nosa Plugs par Analyst Group.

Voir plus
Analys

Nosa Plugs Q3-26

Scalability Becomes Visible Nosa Plugs AB (”Nosa Plugs” or the ”Company”) is a medical technology company that has developed intranasal breathing products for applications such as odor protection and olfactory training,

Axel Ljunghammer

Kommentar

Comments on Nosa Plugs’ Q3 Report

Nosa Plugs AB (“Nosa Plugs” or “the Company”) published its interim report for the third quarter of 2026 on November 6, 2026. The following are some of the points we have chosen to highlight in connection with the report

Axel Ljunghammer

Kommentar

Comment on Nosa Plugs’ Distribution Agreement With Galls in the US

Nosa Plugs AB (”Nosa Plugs” or ”the Company”) announced on 2 October 2026 that it has entered into a distribution agreement with Galls LLC (”Galls”) for sales of Odor Control in the US. The agreement is signed through th

Axel Ljunghammer

Source : Analyst Group. Mis à jour en continu.

S'abonner aux communiqués

Recevez communiqués et rapports par e-mail via MFN.

S'abonner

Contact IR

Adrian Liljefors

VD

ir@nosaplugs.com

Company details

Company
Nosa Plugs AB (publ)
Address
Surbrunnsgatan 42, 113 48 Stockholm, Sverige
Phone
+46 (0)771 112 000